Licensing status

Publication and contact information


Acute myelogenous leukemia (AML)

Notch 1 (NOTCH1)

Two studies in vitro and in mice suggest NOTCH pathway activation could help treat AML. In human AML samples and in a mouse model for the cancer, NOTCH-mediated activation of target genes and NOTCH1 mRNA were lower than those in samples from healthy controls. In AML mouse models, increasing NOTCH pathway signaling led to greater cancer cell apoptosis, differentiation and cell cycle arrest than control treatments. Next steps include developing a stable peptide or small molecule agonist of the NOTCH pathway.

SciBX 6(8); doi:10.1038/scibx.2013.186
Published online Feb. 28, 2013

Patent and licensing status unavailable for findings in first study

Findings in second study unpatented; available for licensing

Lobry, C. et al. J. Exp. Med.; published online Jan. 28, 2013;
Contact: Iannis Aifantis, New York University School of Medicine, New York, N.Y.

Contact: Camille Lobry, same affiliation as above

Kannan, S. et al. J. Exp. Med.; published online Jan. 28, 2013;
Contact: Patrick A.
Zweidler-McKay, The University of Texas MD Anderson Cancer Center, Houston, Texas